Identifying the potential for cytokine release is a critical aspect of pre-clinical safety assessment. However, achieving a full picture of the risks can be cumbersome and time-consuming with today’s commonly used methods. A recent study shows the potential for a faster yet more comprehensive approach. Author, Erika Fletcher, PhD says “when any component is
removed or inactivated for an assay, or when the blood is stored for any period of time, the system is disrupted and the assay’s clinical relevance is diminished…”
Click here to download the white paper and to get crucial insights on how to secure conclusive results for your IND- or CTA-filing.